JP2016531907A - 免疫刺激のためのｃｄ２７アゴニストと免疫チェックポイント阻害との組み合わせ - Google Patents

免疫刺激のためのｃｄ２７アゴニストと免疫チェックポイント阻害との組み合わせ Download PDF

Info

Publication number
JP2016531907A
JP2016531907A JP2016531574A JP2016531574A JP2016531907A JP 2016531907 A JP2016531907 A JP 2016531907A JP 2016531574 A JP2016531574 A JP 2016531574A JP 2016531574 A JP2016531574 A JP 2016531574A JP 2016531907 A JP2016531907 A JP 2016531907A
Authority
JP
Japan
Prior art keywords
antibody
human
immune checkpoint
stimulation
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016531574A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016531907A5 (enExample
Inventor
ファン・エーネンナーム，ハンス
ファン・エルサス，アンドレア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aduro Biotech Holdings Europe BV
Original Assignee
Aduro Biotech Holdings Europe BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aduro Biotech Holdings Europe BV filed Critical Aduro Biotech Holdings Europe BV
Publication of JP2016531907A publication Critical patent/JP2016531907A/ja
Publication of JP2016531907A5 publication Critical patent/JP2016531907A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP2016531574A 2013-08-02 2014-08-02 免疫刺激のためのｃｄ２７アゴニストと免疫チェックポイント阻害との組み合わせ Pending JP2016531907A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NL2011262 2013-08-02
NL2011262 2013-08-02
NL2012361 2014-03-04
NL2012361 2014-03-04
PCT/NL2014/050543 WO2015016718A1 (en) 2013-08-02 2014-08-02 Combining cd27 agonists and immune checkpoint inhibition for immune stimulation

Publications (2)

Publication Number Publication Date
JP2016531907A true JP2016531907A (ja) 2016-10-13
JP2016531907A5 JP2016531907A5 (enExample) 2017-09-07

Family

ID=51494473

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016531574A Pending JP2016531907A (ja) 2013-08-02 2014-08-02 免疫刺激のためのｃｄ２７アゴニストと免疫チェックポイント阻害との組み合わせ

Country Status (11)

Country Link
US (3) US20160185870A1 (enExample)
EP (1) EP3027210A1 (enExample)
JP (1) JP2016531907A (enExample)
KR (1) KR20160037989A (enExample)
CN (1) CN105682683A (enExample)
AU (1) AU2014296887A1 (enExample)
BR (1) BR112016001420A2 (enExample)
CA (1) CA2917858A1 (enExample)
MX (1) MX2016000750A (enExample)
RU (1) RU2016107426A (enExample)
WO (1) WO2015016718A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020136879A1 (ja) * 2018-12-28 2020-07-02 国立大学法人大阪大学 悪性腫瘍を治療するための免疫療法剤の有用性の提示方法及び悪性腫瘍を治療するための免疫療法剤
US12259379B2 (en) 2017-06-30 2025-03-25 Osaka University Method for predicting effect of tumor immunotherapy using tumor cytotoxic activity of peripheral blood T cells as index

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011239706B2 (en) 2010-04-13 2015-08-20 Celldex Therapeutics Inc. Antibodies that bind human CD27 and uses thereof
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
US9789182B2 (en) * 2012-10-23 2017-10-17 Bristol-Myers Squibb Company Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
WO2014071419A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
AU2014207342C1 (en) 2013-01-18 2019-04-04 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
EA036902B1 (ru) 2013-09-20 2021-01-13 Бристол-Майерс Сквибб Компани Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
LT3081576T (lt) 2013-12-12 2019-10-25 Shanghai hengrui pharmaceutical co ltd Pd-1 antikūnas, antigeną surišantis jo fragmentas ir jų medicininis pritaikomumas
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
SG11201700700YA (en) * 2014-08-01 2017-02-27 3M Innovative Properties Co Methods and therapeutic combinations for treating tumors
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
GB201419084D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
JP6952603B2 (ja) 2015-02-10 2021-10-20 オハイオ・ステイト・イノベーション・ファウンデーション クラミジア活性化ｂ細胞プラットフォーム及びその方法
WO2016145085A2 (en) * 2015-03-09 2016-09-15 Celldex Therapeutics, Inc. Cd27 agonists
AU2016235434B2 (en) * 2015-03-20 2022-02-03 Syndax Pharmaceuticals, Inc. Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
EP3283882B2 (en) 2015-04-17 2024-10-16 Merck Sharp & Dohme LLC Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
DK3291679T3 (da) 2015-05-06 2022-01-17 Snipr Tech Ltd Ændring af mikrobielle populationer og modificering af mikrobiota
EP3892284B1 (en) 2015-05-29 2024-05-22 Merck Sharp & Dohme LLC Combination of a pd-1 antagonist and a cpg-c type oligonucleotide for treating cancer
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
CN107921087A (zh) 2015-07-16 2018-04-17 百欧肯治疗有限公司 治疗癌症的组合物及方法
US10894044B2 (en) 2015-09-16 2021-01-19 Board Of Regents, The University Of Texas System Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer
DK3356401T3 (da) * 2015-09-30 2020-09-07 Igm Biosciences Inc Bindingsmolekyler med modificeret j-kæde
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
TWI805542B (zh) * 2015-10-23 2023-06-21 日商坎巴斯有限公司 用於癌症治療之肽及擬肽與ｔ細胞活化劑及／或查核點抑制劑之組合
US10149887B2 (en) * 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
EP3364995B1 (en) * 2015-10-23 2021-08-04 Apogenix AG Single-chain cd27-receptor agonist proteins
LT3370733T (lt) 2015-11-02 2021-10-25 Board Of Regents, The University Of Texas System Cd40 aktyvinimo ir imuninės kontrolės taškų blokados būdai
JP6859954B2 (ja) * 2015-11-04 2021-04-14 アステラス製薬株式会社 ジアミノヘテロ環カルボキサミド化合物を有効成分とするがん免疫治療用、及び／又は、免疫活性化用医薬組成物
WO2017079746A2 (en) 2015-11-07 2017-05-11 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
WO2017083337A1 (en) 2015-11-10 2017-05-18 Ohio State Innovation Foundation Methods and compositions related to accelerated humoral affinity
KR20180086502A (ko) 2015-12-16 2018-07-31 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항원-결합 단편
EP4299136A3 (en) 2015-12-16 2024-02-14 Gritstone bio, Inc. Neoantigen identification, manufacture, and use
KR20180089444A (ko) 2015-12-22 2018-08-08 리제너론 파아마슈티컬스, 인크. 암을 치료하기 위한 항-pd-1 항체와 이특이적 항-cd20/항-cd3 항체의 조합
WO2017123643A1 (en) * 2016-01-11 2017-07-20 Flagship Pioneering, Inc. Methods and compositions for modulating thymic function
KR102033920B1 (ko) 2016-02-23 2019-10-18 바이오라인알엑스 리미티드 급성 골수성 백혈병을 치료하는 방법
EP3436480A4 (en) 2016-03-30 2019-11-27 Musc Foundation for Research Development METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION
WO2017184619A2 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
EP3449017B1 (en) 2016-04-29 2021-12-22 Board of Regents, The University of Texas System Targeted measure of transcriptional activity related to hormone receptors
TWI822521B (zh) 2016-05-13 2023-11-11 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
MY195089A (en) 2016-05-27 2023-01-10 Agenus Inc Anti-Tim-3 Antibodies and Methods of use thereof
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
CN109563481B (zh) 2016-07-13 2024-01-05 俄亥俄州创新基金会 用于优化宿主抗原呈递和宿主抗肿瘤和抗病原体免疫的平台和方法
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
AU2017335732B2 (en) 2016-09-27 2024-11-21 Board Of Regents, The University Of Texas System Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome
IL265800B2 (en) 2016-10-11 2023-10-01 Agenus Inc Anti-LAG-3 antibodies and methods of using them
CN110072540B (zh) 2016-10-12 2023-06-02 得克萨斯州大学系统董事会 用于tusc2免疫治疗的方法和组合物
WO2018089423A1 (en) 2016-11-09 2018-05-17 Musc Foundation For Research Development Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
WO2018094225A1 (en) 2016-11-17 2018-05-24 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 mutations
IL311265A (en) 2016-12-05 2024-05-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
PT3551660T (pt) 2016-12-07 2023-11-30 Ludwig Inst For Cancer Res Ltd Anticorpos anti-ctla-4 e métodos de uso dos mesmos
EP3551226A1 (en) 2016-12-12 2019-10-16 MultiVir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
CN110612447B (zh) 2017-02-24 2024-02-06 德克萨斯州立大学董事会 用于检测早期胰腺癌的测定
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
JP7537874B2 (ja) 2017-05-19 2024-08-21 シンダックス ファーマシューティカルズ， インコーポレイテッド 併用療法
EP3630179A2 (en) 2017-05-30 2020-04-08 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
PT3631454T (pt) 2017-05-30 2023-11-23 Bristol Myers Squibb Co Tratamento de tumores positivos para lag-3
WO2019040780A1 (en) 2017-08-25 2019-02-28 Five Prime Therapeutics Inc. ANTI-B7-H4 ANTIBODIES AND METHODS OF USE
EP3694532B1 (en) 2017-10-10 2025-02-26 Gritstone bio, Inc. Neoantigen identification using hotspots
AU2018346957B2 (en) 2017-10-12 2024-08-01 Board Of Regents, The University Of Texas System T cell receptors for immunotherapy
IL274799B2 (en) 2017-11-22 2025-05-01 Gritstone Bio Inc Reducing junction epitope presentation for neoantigens
US20190241660A1 (en) * 2017-12-05 2019-08-08 Intendet Services, Llc Immune-stimulating peptides and checkpoint inhibitors, and uses thereof for treating cancer
AU2019226011B2 (en) 2018-02-21 2025-11-27 Five Prime Therapeutics, Inc. B7-H4 antibody formulations
CN111971308A (zh) 2018-03-02 2020-11-20 戊瑞治疗有限公司 B7-h4抗体及其使用方法
AU2019322487B2 (en) 2018-03-19 2024-04-18 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
KR20210006344A (ko) 2018-03-25 2021-01-18 에스엔아이피알 바이옴 에이피에스. 미생물 감염의 치료 및 예방
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
CA3094108A1 (en) 2018-03-27 2019-10-03 Board Of Regents, The University Of Texas Systems Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
WO2019191429A2 (en) 2018-03-28 2019-10-03 Board Of Regents, The University Of Texas System Identification of epigenetic alterations in dna isolated from exosomes
JP7466459B2 (ja) 2018-04-17 2024-04-12 セルデックス セラピューティクス インコーポレイテッド 抗ｃｄ２７および抗ｐｄ－ｌ１抗体ならびに二重特異性構築物
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
WO2020106621A1 (en) 2018-11-19 2020-05-28 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
EA202191463A1 (ru) 2018-11-28 2021-10-13 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Мультиплексное редактирование генома иммунных клеток для повышения функциональности и устойчивости к подавляющей среде
CN113316455A (zh) 2018-11-29 2021-08-27 得克萨斯大学体系董事会 用于离体扩增自然杀伤细胞的方法及其用途
CN120468425A (zh) * 2019-01-30 2025-08-12 国家医疗保健研究所 用于鉴定患有癌症的受试者是否将获得对免疫检查点抑制剂的应答的方法和组合物
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
US12492380B2 (en) 2019-05-09 2025-12-09 FUJIFILM Cellular Dynamics, Inc. Methods for the production of hepatocytes
JP2022532766A (ja) 2019-05-17 2022-07-19 キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド 家族性腺腫性ポリポーシスを処置するための方法
WO2021087458A2 (en) 2019-11-02 2021-05-06 Board Of Regents, The University Of Texas System Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
TWI895295B (zh) 2019-11-12 2025-09-01 美商方得生醫療公司 偵測編碼新生抗原之融合基因之方法
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
US12251449B2 (en) 2019-12-19 2025-03-18 William Marsh Rice University Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase
WO2021141977A1 (en) 2020-01-07 2021-07-15 Board Of Regents, The University Of Texas System Improved human methyl thioadenosine/adenosine depleting enzyme variants for cancer therapy
JP2023513006A (ja) 2020-01-29 2023-03-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｎｒｇ１融合体を有するがんの治療のためのｅｇｆｒ／ｈｅｒ２チロシンキナーゼインヒビターおよび／またはｈｅｒ２／ｈｅｒ３抗体の使用
EP4096789A4 (en) 2020-01-29 2023-10-11 Board of Regents, The University of Texas System USE OF POZIOTINIB TO TREAT CANCER WITH NRG1 FUSIONS
EP4107173A1 (en) 2020-02-17 2022-12-28 Board of Regents, The University of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
US20230114276A1 (en) * 2020-03-06 2023-04-13 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Modulating anti-tumor immunity
EP4153301A2 (en) 2020-05-21 2023-03-29 Board of Regents, The University of Texas System T cell receptors with vgll1 specificity and uses thereof
WO2021247836A1 (en) 2020-06-03 2021-12-09 Board Of Regents, The University Of Texas System Methods for targeting shp-2 to overcome resistance
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
WO2022104109A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
AU2021388155A1 (en) 2020-11-25 2023-06-15 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
CA3205538A1 (en) 2021-01-19 2022-07-28 Han XIAO Bone-specific delivery of polypeptides
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
EP4363059A1 (en) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
AU2022324040A1 (en) 2021-08-04 2024-02-22 The Regents Of The University Of Colorado, A Body Corporate Lat activating chimeric antigen receptor t cells and methods of use thereof
CN118369419A (zh) 2021-10-05 2024-07-19 赛托维亚治疗有限责任公司 自然杀伤细胞及其使用方法
KR20240099161A (ko) 2021-10-20 2024-06-28 다케다 야쿠힌 고교 가부시키가이샤 Bcma를 표적화하는 조성물 및 이의 사용 방법
WO2023076880A1 (en) 2021-10-25 2023-05-04 Board Of Regents, The University Of Texas System Foxo1-targeted therapy for the treatment of cancer
WO2023172514A1 (en) 2022-03-07 2023-09-14 Catamaran Bio, Inc. Engineered immune cell therapeutics targeted to her2 and methods of use thereof
EP4514382A1 (en) 2022-04-28 2025-03-05 Musc Foundation for Research Development Chimeric antigen receptor modified regulatory t cells for treating cancer
WO2023220083A1 (en) 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods of use for treating proliferative disorders
CN119451985A (zh) 2022-05-12 2025-02-14 健玛保 在组合疗法中能够结合cd27的结合剂
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
EP4598946A1 (en) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2025217275A2 (en) 2024-04-10 2025-10-16 Flagship Pioneering Innovations Vii, Llc Immune cell targeted compositions and related methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010506925A (ja) * 2006-10-20 2010-03-04 ユニバーシティ・オブ・サザンプトン Ｃｄ２７アゴニストを単独でまたは他の免疫調節剤と併用して用いる、ヒト免疫療法
WO2011130434A2 (en) * 2010-04-13 2011-10-20 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
WO2012004367A1 (en) * 2010-07-09 2012-01-12 N.V. Organon Agonistic antibody to cd27

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5229289A (en) 1988-03-11 1993-07-20 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human and with synthetic carbohydrate-carrier conjugates
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
US20030035790A1 (en) 1999-01-15 2003-02-20 Shu-Hsia Chen Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
US20070134247A9 (en) 2002-04-12 2007-06-14 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
EP1578419A4 (en) 2002-12-30 2008-11-12 3M Innovative Properties Co IMMUNOSTIMULATING COMBINATIONS
US7728114B2 (en) 2004-06-03 2010-06-01 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
US20110142858A1 (en) 2004-06-07 2011-06-16 Ramot At Tel Aviv University Ltd. Method of Passsive Immunization Against Disease or Disorder Charcterized by Amyloid Aggregation with Diminished Risk of Neuroinflammation
AU2005259221B2 (en) 2004-07-01 2011-02-10 Innate Pharma Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
WO2006005770A2 (en) 2004-07-15 2006-01-19 Technische Universität Wien Method for the detection of fusarium graminearum
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EP3910065B8 (en) 2006-09-08 2025-09-17 AbbVie Manufacturing Management Unlimited Company Interleukin -13 binding proteins
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
SI2170959T1 (sl) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. Protitelesa proti receptorjem pd-1 za humano programirano smrt
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
CA2729567C (en) 2008-06-30 2018-04-24 Kyowa Hakko Kirin Co., Ltd. Anti-cd27 antibody
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
FI4209510T3 (fi) 2008-12-09 2024-03-22 Hoffmann La Roche Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi
EA201270228A1 (ru) 2009-07-31 2012-09-28 Медарекс, Инк. Полноценные человеческие антитела к btla
JP2013503204A (ja) 2009-08-31 2013-01-31 アンプリミューン， インコーポレイテッド Ｂ７−ｈ４融合タンパク質およびその使用方法
LT3279215T (lt) 2009-11-24 2020-04-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
AU2013203270B2 (en) * 2010-04-13 2016-05-19 Celldex Therapeutics Inc. Antibodies that bind human CD27 and uses thereof
PL2691112T3 (pl) 2011-03-31 2018-09-28 Merck Sharp & Dohme Corp. Stabilne preparaty przeciwciał przeciw ludzkiemu receptorowi programowanej śmierci pd-1 i terapie powiązane
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
AU2012296613B2 (en) 2011-08-15 2016-05-12 Amplimmune, Inc. Anti-B7-H4 antibodies and their uses
ES2861435T3 (es) 2011-11-03 2021-10-06 Univ Pennsylvania Composiciones específicas de B7-H4 aisladas y métodos de uso de las mismas
AR091649A1 (es) * 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
ES2901712T3 (es) 2012-08-16 2022-03-23 Novartis Ag Combinación de un inhibidor de pi3k y un inhibidor de c-met.
TWI693232B (zh) * 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010506925A (ja) * 2006-10-20 2010-03-04 ユニバーシティ・オブ・サザンプトン Ｃｄ２７アゴニストを単独でまたは他の免疫調節剤と併用して用いる、ヒト免疫療法
WO2011130434A2 (en) * 2010-04-13 2011-10-20 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
WO2012004367A1 (en) * 2010-07-09 2012-01-12 N.V. Organon Agonistic antibody to cd27

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CANCER IMMUNOLOGY RESEARCH, vol. 2, no. 9, JPN6018021276, 28 May 2014 (2014-05-28), pages 846 - 856, ISSN: 0004004942 *
LANCET, vol. 384, JPN6018021274, 15 July 2014 (2014-07-15), pages 1109 - 1117, ISSN: 0004004941 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12259379B2 (en) 2017-06-30 2025-03-25 Osaka University Method for predicting effect of tumor immunotherapy using tumor cytotoxic activity of peripheral blood T cells as index
WO2020136879A1 (ja) * 2018-12-28 2020-07-02 国立大学法人大阪大学 悪性腫瘍を治療するための免疫療法剤の有用性の提示方法及び悪性腫瘍を治療するための免疫療法剤

Also Published As

Publication number Publication date
US20160185870A1 (en) 2016-06-30
MX2016000750A (es) 2016-08-05
AU2014296887A1 (en) 2016-01-28
US20190135933A1 (en) 2019-05-09
EP3027210A1 (en) 2016-06-08
US12168693B2 (en) 2024-12-17
US20250179206A1 (en) 2025-06-05
BR112016001420A2 (pt) 2018-01-23
RU2016107426A3 (enExample) 2018-06-28
WO2015016718A1 (en) 2015-02-05
CN105682683A (zh) 2016-06-15
KR20160037989A (ko) 2016-04-06
CA2917858A1 (en) 2015-02-05
RU2016107426A (ru) 2017-09-07

Similar Documents

Publication Publication Date Title
US20250179206A1 (en) Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
Carter et al. Next generation antibody drugs: pursuit of the'high-hanging fruit'
US11673952B2 (en) Antibodies specific to delta 1 chain of T cell receptor
CN108738324B (zh) 抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)抗体及其用途
JP6900323B2 (ja) 抗ｃｔｌａ−４抗体およびその使用方法
RU2691428C2 (ru) Антитела к h7cr
EP3630838A1 (en) Activatable anti-pdl1 antibodies, and methods of use thereof
WO2018187613A2 (en) Anti-icos agonist antibodies and uses thereof
JP7274426B2 (ja) 抗ｇｉｔｒアゴニスト抗体での癌の処置
JP2019521645A (ja) ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
CN108112254A (zh) 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
IL263611A (en) Antibodies specific to PD-L1 and methods of using them
EP3402519A1 (en) Multispecific immunomodulatory antigen-binding constructs
WO2016115274A1 (en) Multispecific immunomodulatory antigen-binding constructs
TW201625694A (zh) 與４-１ｂｂ結合之分子類
AU2017362721A1 (en) Anti-GITR antigen-binding proteins and methods of use thereof
CN117377692A (zh) Tim-3-靶向抗体及其用途
CN116134053A (zh) 用于使用PD-1 x CTLA-4双特异性分子的方法
EP4581058A2 (en) Methods for treating cancer using anti-ctla4 antibodies
HK40104690A (zh) Tim-3-靶向抗体及其用途
CA3064588A1 (en) Activatable anti-pdl1 antibodies, and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170731

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180612

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181112

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190402